https://doi.org/10.55788/318bec28
The final follow-up data of the primary outcome of the phase 3 OPAS-1 trial suggested that 8 courses of S-1 adjuvant chemotherapy is the preferred option over 4 courses of this treatment regimen in patients with stage 2 gastric cancer who underwent resection.
The OPAS-1 trial (UMIN000007306) compared the standard-of-care treatment for patients with pathological stage 2 gastric cancer who underwent D2 gastrectomy, which is 8 courses of S-1 adjuvant chemotherapy, to a shortened version of this therapy, namely 4 courses [1]. In total, 590 patients were randomised to one of the 2 study groups. At the first interim analysis, the study was closed due to futility and it demonstrated that 4-courses of S-1 led to slightly inferior results in terms of relapse-free survival (RFS) compared with 8 courses [2]. Dr Souya Nunobe (Cancer Institute Hospital, Japan) presented the updated results of the trial.
The 5-year RFS rates displayed a slight numerical benefit for patients who had received 8 courses of S-1 compared with those who had received only 4 courses of this therapy (87.7% vs 85.6%; HR 1.27; 95% CI 0.85–1.89). The 5-year overall survival rates were 89.7% in the standard-of-care arm and 88.6% in the experimental arm (HR 1.12; 95% CI 0.72–1.75).
According to Dr Nunobe, 8 courses of S-1 adjuvant chemotherapy is highly recommended in Japanese guidelines in patients with pathological stage 2 gastric cancer.
- Nunobe S, et al. Five-year follow-up results of a randomized phase III trial comparing 4 and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer: JCOG1104 (OPAS-1). Abstract 381, ASCO GI 2023, 19–21 January, San Francisco, CA, USA.
- Yoshikawa T, et al. Annals of Oncology. 2017;28(5):V214.
Copyright ©2023 Medicom Medical Publishers
Posted on
« LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer Next Article
Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial »
Table of Contents: ASCO GI 2023
Featured articles
Oesophageal and Gastric Cancer
Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer
Regorafenib offers survival benefit for patients with pre-treated gastric cancer
Radiotherapy or not in locally advanced oesophageal or junctional cancer?
Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial
S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer?
LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer
3-year follow-up data confirms benefits of nivolumab plus chemotherapy
Long-term results for nivolumab plus chemotherapy and nivolumab plus ipilimumab in oesophageal cancer
Promising phase 2 results for HER-Vaxx in gastric cancer
Anal and Colorectal Cancer
IMbrave 151 missed primary endpoint in advanced BTC
Combination botensilimab plus balstilimab demonstrates promising activity in heavily pre-treated MSS CRC
Mutation-based selection to identify patients suitable for panitumumab treatment
Fucoidan associated with quality-of-life benefits in patients with rectal cancer receiving CCRT
ctDNA appears useful in monitoring patients with anal cancer undergoing CRT
SUNLIGHT trial meets primary endpoint in refractory metastatic CRC
Does cell-free DNA influence MRD testing in post-operative colon cancer?
OPERA: surgery may be avoided with adequate therapy in rectal cancer
Can we improve total neoadjuvant therapy for rectal cancer?
Hepatobiliary Cancer
Palliative radiation therapy improves hepatic pain in HCC and liver metastasis
Improved survival following postoperative sorafenib plus TACE in HCC
Quality-of-life benefits for tislelizumab in uHCC
Stereotactic body radiation therapy beneficial for patients with locally advanced HCC
SWOG 1815, first-ever phase 3 trial in BTC, fails
Acceptable safety profile and encouraging efficacy of nanvuranlat in BTC
Pancreatic Cancer
First-line NALIRIFOX superior to standard treatment in mPDAC
Novel approach delivers quality-of-life benefits for patients with pancreatic cancer
Related Articles
Can we improve total neoadjuvant therapy for rectal cancer?

© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy